EDMONTON, July 18, 2013 /CNW/ - Medwell Capital Corp. (TSX-V: MWC) today
announces that its wholly owned Medwell Healthcare Investments Limited
Partnership ("Medwell LP") is increasing its previously disclosed new
investment in Mimetogen Pharmaceuticals Inc. (Mimetogen") from $400,000
to $800,000. In total, Medwell LP will have invested a total of $2.8m
and will own 11.3% of Mimetogen on a fully diluted basis.
Mimetogen today announced that it has entered into a transaction with
Bausch + Lomb in respect of its MIM-D3 technology for the treatment of
dry eye syndrome. For details please see Medwell's website, or
Mimetogen's website at www.mimetogen.com
About Medwell Capital Corp.
Medwell Capital Corp. is a Canadian-based investment and advisory firm.
For further information please visit www.medwellcapital.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This press release may contain forward-looking statements, which
reflect the Company's current expectation regarding future events.
These forward-looking statements involve risks and uncertainties that
may cause actual results, events or developments to be materially
different from any future results, events or developments expressed or
implied by such forward-looking statements. Such factors include, but
are not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process
and other risks detailed from time to time in the Corporation's ongoing
quarterly and annual reporting. We undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE: Medwell Capital Corp.
For further information:
Medwell Capital Corp.
416-815-0700 ext. 238